Sana Biotechnology, Inc. — Form 4
Filed August 27, 2026 · analyzed by the Insider Agent
4
— Neutral
significance 22/100
What the filing says
EVP, Chief Scientific Officer PATEL DHAVALKUMAR DHIRAJLAL (SANA) exercised options for 125K shares. Routine compensation — limited price signal.
Why this rating
Routine compensation — limited price signal.
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.